Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium
Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease highlight shared and tissue-specific effects
Nat Genet
Jun 01, 2025
57 (6) :1426-1436
Stimming EF, Claassen DO, Sen GP, Klepitskaya O, Serbin M, Kim H, Hinton SC, Haubenberger D
Longitudinal treatment patterns of chorea in North American patients with Huntington's disease: Data from Enroll-HD
Neurol Ther
Jun 01, 2025
14 (3) :743-756
Boareto M, Yamamoto Y, Long JD, Sampaio C, McColgan P, Diack C, Ducray PS
Modeling disease progression and placebo response in Huntington disease: Insights from Enroll-HD and GENERATION HD1 cohorts
Neurology
May 27, 2025
104 (10) :e213646
Bakels HS, van der Zwaan KF, Van Zwet E, Reijntjes R, Sprenger GP, Knecht TA, Roos RAC, de Bot ST
Comparison of the clinical spectrum of juvenile- and adult-onset Huntington disease: A national cohort and Enroll-HD observational study
Neurology
May 27, 2025
104 (10) :e213525
Geva M, Goldberg YP, Schuring H, Tan AM, Long JD, Hayden MR
Antidopaminergic medications and clinical changes in measures of Huntington's disease: A causal analysis
Mov Disord
May 01, 2025
40 (5) :928-937
Halabi N, Killoran A, Nopoulos PC, Schultz JL
Differentiating hyperkinetic and hypokinetic motor features in the progression of Huntington's disease
MedRxiv [Preprint]
Abr 21, 2025
Gil-Salcedo A, Lunven M, Jacquemot C, Massart R, Bachoud-Levi AC
Specific contribution of cognitive and motor impairments with functional capacity and dependence in Huntington's disease
J Neurol
Feb 22, 2025
272 (3) :224
van der Zwaan KF, Feleus S, Dekkers OM, Roos RAC, de Bot ST
Total functioning capacity scale in Huntington's disease: natural course over time
J Neurol
Ene 15, 2025
272 (2) :140
Feleus S, Vo MTD, Kuijper LCM, Roos RAC, de Bot ST
Cognitive impairment predicts medication discrepancies in Huntington's disease: patient self-report compared to pharmacy records
J Neurol
Ene 02, 2025
272 (1) :55
Schultz JL, Ogilvie AC, Harshman LA, Nopoulos PC
β-blocker use and delayed onset and progression of Huntington disease
JAMA Neurol
Ene 01, 2025
82 (1) :85-92
Feleus S, Skotnicki LEM, Roos RAC, de Bot ST
Medication use and treatment indications in Huntington's disease; analyses from a large cohort
Mov Disord Clin Pract
Dic 19, 2024
11 (12) :1530-1541
Khetarpal V, Herbst T, Dominguez C, Munoz-Sanjuan I, Sampaio C, Marks B, Miller D, Farnham J, Ledvina A, Anglehart H, Rehmani I, LaFayette A, Spridco N, Langbehn D, Wild EJ, Pacifici R
Lack of evidence for kynurenine pathway dysfunction in Huntington’s disease: Cerebrospinal fluid and plasma analyses from the HDClarity study
J Huntingtons Dis
Dic 10, 2024
Funcis A, Ravera B, Zinzi P, Solito M, Petracca M, Calabresi P, Bentivoglio AR
Neuroleptic malignant syndrome in Huntington disease
Eur J Neurol
Dic 01, 2024
31 (12) :e16442
Pollard A, Greetham D, Myatt J, Rickards H, Stanley C, Dungate D
Data-driven Huntington's disease progression modelling and estimation of societal cost in the UK
R Soc Open Sci
Nov 20, 2024
11 (11) :240824
Yao J, Feng B S G, Shao M S G, Mendizabal A, Telesca D, Fang K, Ibragimova L, Shoaib J, Morrison MA, Lupo JM
Interplay between sex and disease burden in Huntington's disease: Clinical and neuroimaging perspectives
MedRxiv [Preprint]
Nov 02, 2024
Gray SM, Dai J, Smith AC, Beckley JT, Rahmati N, Lewis MC, Quirk MC
Changes in 24(S)-hydroxycholesterol are associated with cognitive performance in early Huntington's disease: Data from the TRACK and ENROLL HD cohorts
J Huntingtons Dis
Nov 01, 2024
13 (4) :449-465
Di Cecca A, Ilardi CR, Della Pia F, Criscuolo C, Della Sala S, Salvatore E
Distortion errors characterise visuo-constructive performance in Huntington's disease
Clin Neuropsychol
Oct 11, 2024
:1-19
Mendizabal A, Ogilvie AC, Bordelon Y, Perlman SL, Brown A
Racial disparities in time to Huntington disease diagnosis in North America: An Enroll-HD analysis
Neurol Clin Pract
Oct 01, 2024
14 (5) :e200344
Mills JA, Long JD, Vaidya JG, Gantman EC, Sathe S, Tabrizi SJ, Sampaio C
Time to functional loss as an endpoint in Huntington's disease trials: Enrichment and sample size
Mov Disord
Oct 01, 2024
39 (10) :1809-1816
Guzauskas GF, Tabrizi SJ, Long JD, Arnesen A, Hamilton JL, Claassen DO, Munetsi LR, Malik S, Rodríguez-Santana I, Ali TM, Zhang F
Long-term health outcomes of Huntington disease and the impact of future disease-modifying treatments: A decision-modeling analysis
Neurol Clin Pract
Oct 01, 2024
14 (5) :e200340
Schoenmakers DH, van den Berg S, Timmers L, Adang LA, Bäumer T, Bosch A, van de Casteele M, Datema MR, Dekker H, Donnelly C, Driessens MHE, Graessner H, Greger V, Haddad T, Höglinger GU, van den Hout H, Jonker C, Langeveld M, Lambert LJ, Neacy E, ...Wolf NI
Framework for multistakeholder patient registries in the field of rare diseases: Focus on neurogenetic diseases
Neurology
Sep 24, 2024
103 (6) :e209743
Bakels HS, Feleus S, Rodríguez-Girondo M, Losekoot M, Bijlsma EK, Roos RAC, de Bot ST
Prevalence of juvenile-onset and pediatric Huntington's disease and their availability and ability to participate in trials: A Dutch population and Enroll-HD observational study
J Huntingtons Dis
Sep 10, 2024
13 (3) :357-368
Ioakeimidis V, Busse M, Drew CJG, Pallmann P, Watson GB, Jones D, Palombo M, Schubert R, Rosser AE, Metzler-Baddeley C
Protocol for a randomised controlled unblinded feasibility trial of HD-DRUM: a rhythmic movement training application for cognitive and motor symptoms in people with Huntington's disease
BMJ Open
Jul 31, 2024
14 (7) :e082161
Ruiz de Sabando A, Ciosi M, Galbete A, Cumming SA, Spanish HD Collaborative Group, Monckton DG, Ramos-Arroyo MA
Somatic CAG repeat instability in intermediate alleles of the HTT gene and its potential association with a clinical phenotype
Eur J Hum Genet
Jul 01, 2024
32 (7) :770-778
Gil-Salcedo A, Massart R, de Langavant LC, Bachoud-Levi AC
Modifiable factors associated with Huntington's disease progression in presymptomatic participants
Ann Clin Transl Neurol
Jul 01, 2024
11 (7) :1930-1941
Sprenger GP, van Zwet EW, Bakels HS, Achterberg WP, Roos RA, de Bot ST
Prevalence and burden of pain across the entire spectrum of Huntington's disease
J Neurol Neurosurg Psychiatry
Jun 17, 2024
95 (7) :647-655
Delussi M, Valt C, Silvestri A, Ricci K, Ladisa E, Ammendola E, Rampino A, Pergola G, de Tommaso M
Auditory mismatch negativity in pre-manifest and manifest Huntington's disease
Clin Neurophysiol
Jun 01, 2024
162 :121-128
Lozano-Garcia M, Doheny EP, Mann E, Morgan-Jones P, Drew C, Busse-Morris M, Lowery MM
Estimation of gait parameters in Huntington's disease using wearable sensors in the clinic and free-living conditions
IEEE Trans Neural Syst Rehabil
May 31, 2024
Raschka T, Li Z, Gaßner H, Kohl Z, Jukic J, Marxreiter F, Fröhlich H
Unraveling progression subtypes in people with Huntington's disease
EPMA J
May 28, 2024
15 (2) :275-287
Fahed VS, Doheny EP, Collazo C, Krzysztofik J, Mann E, Morgan-Jones P, Mills L, Drew C, Rosser AE, Cousins R, Witkowski G, Cubo E, Busse M, Lowery MM
Language-independent acoustic biomarkers for quantifying speech impairment in Huntington's disease
Am J Speech Lang Pathol
May 01, 2024
33 (3) :1-16
Migliore S, Bianco SD, Scocchia M, Maffi S, Busi LC, Ceccarelli C, Curcio G, Mazza T, Squitieri F
Prodromal cognitive changes as a prognostic indicator of forthcoming Huntington's disease severity: A retrospective longitudinal study
Mov Disord Clin Pract
Abr 02, 2024
11 (4) :363-372
Knights H, Coleman A, Hobbs NZ, Tabrizi SJ, Scahill RI, HD-YAS investigators
Freesurfer software update significantly impacts striatal volumes in the Huntington's disease young adult study and will influence HD-ISS staging
J Huntingtons Dis
Mar 29, 2024
13 (1) :77-90
Pfalzer AC, Shiino S, Silverman J, Codreanu SG, Sherrod SD, McLean JA, Claassen DO
Alterations in cerebrospinal fluid urea occur in late manifest Huntington's disease
J Huntingtons Dis
Mar 29, 2024
13 (1) :103-111
Gaudet ID, Xu H, Gordon E, Cannestro GA, Lu ML, Wei J
Elevated SLC7A2 expression is associated with an abnormal neuroinflammatory response and nitrosative stress in Huntington's disease
J Neuroinflammation
Feb 28, 2024
21 (1) :59
Sun Z, Ware J, Dey S, Eyigoz E, Sathe S, Sampaio C, Hu J
Large-scale screening of clinical assessments to distinguish between states in the Integrated HD Progression Model (IHDPM)
Front Aging Neurosci
Feb 13, 2024
16 :1320755
Nopoulos S, Reasoner EE, Ogilvie AC, Killoran A, Schultz JL
Evaluating motor progression of juvenile-onset Huntington's Disease: An Enroll-HD analysis
Parkinsonism Relat Disord
Feb 01, 2024
119 (105954)
Achenbach J, Stodt B, Saft C
Factors influencing the total functional capacity score as a critical endpoint in Huntington's disease research
Biomedicines
Dic 17, 2023
11 (12) :3336
Jeyakumar N, Hilmer SN, Teixeira-Pinto A, Loy CT
Frailty and associated environmental factors only have small effects on age of onset in Huntington's disease
J Huntingtons Dis
Dic 15, 2023
12 (4) :355-361
Mendizabal A, Singh AP, Perlman S, Brown A, Bordelon Y
Disparities in Huntington disease severity: Analysis using the ENROLL-HD dataset
Neurol Clin Pract
Dic 01, 2023
13 (6) :e200200
Langbehn DR, Sathe SS, Loy C, Sampaio C, Mccusker EA
A phenotypic atlas for Huntington disease based on data from the Enroll-HD cohort study
Neurol Genet
Dic 01, 2023
9 (6) :e200111